Application of high-resolution MRI in evaluating statin efficacy on symptomatic intracranial atherosclerosis.

IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
European Radiology Pub Date : 2025-01-01 Epub Date: 2024-07-19 DOI:10.1007/s00330-024-10968-1
Juan Huang, Cong Liu, Sheng Jiao, Yuhui Chen, Lei Xu, Tao Gong, Chengcheng Zhu, Yan Song
{"title":"Application of high-resolution MRI in evaluating statin efficacy on symptomatic intracranial atherosclerosis.","authors":"Juan Huang, Cong Liu, Sheng Jiao, Yuhui Chen, Lei Xu, Tao Gong, Chengcheng Zhu, Yan Song","doi":"10.1007/s00330-024-10968-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the efficacy of statins on symptomatic intracranial atherosclerotic plaques using high-resolution 3.0 T MR vessel wall imaging (HR-MRI).</p><p><strong>Methods: </strong>Patients with symptomatic intracranial atherosclerotic plaques (cerebral ischemic events within the last three months) confirmed by HR-MRI from July 2017 to August 2022 were retrospectively included in this study. The enrolled patients started statin therapy at baseline. All the patients underwent the follow-up HR-MRI examination after statin therapy for at least 3 months. A paired sample t-test and Wilcoxon rank sum test were used to evaluate the changes in plaque characteristics after statin therapy. Multivariate linear regression was further used to investigate the clinical factors associated with statin efficacy.</p><p><strong>Results: </strong>A total of 48 patients (37 males; overall mean age = 60.2 ± 11.7 years) were included in this study. The follow-up time was 7.0 (5.6-12.0) months. In patients treated with statins for > 6 months (n = 31), plaque length, wall thickness, plaque burden, luminal stenosis and plaque enhancement were significantly reduced. Similar results were found in patients with good lipid control (n = 21). Younger age, lower BMI and hypertension were associated with decreased plaque burden. Lower BMI, hypertension and longer duration of statin therapy were associated with decreased plaque enhancement. Younger age and hypertension were associated with decreased luminal stenosis (all p < 0.05).</p><p><strong>Conclusion: </strong>HR-MRI can effectively evaluate plaques changes after statin therapy. Statins can reduce plaque burden and stabilize plaques. The effect of statin may have a relationship with age, BMI, hypertension, and duration of statin therapy.</p><p><strong>Clinical relevance statement: </strong>High-resolution MRI can be applied to evaluate the efficacy of statins on symptomatic intracranial atherosclerotic plaques. Long-term statin use and well-controlled blood lipid levels can help reduce plaque burden and stabilize plaques.</p><p><strong>Key points: </strong>High-resolution MRI provides great help evaluating the changes of plaque characteristics after statin therapy. Efficacy of statins is associated with duration of use, controlled lipid levels, and clinical factors. High-resolution MRI can serve as an effective method for following-up symptomatic intracranial atherosclerosis.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"441-452"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00330-024-10968-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To investigate the efficacy of statins on symptomatic intracranial atherosclerotic plaques using high-resolution 3.0 T MR vessel wall imaging (HR-MRI).

Methods: Patients with symptomatic intracranial atherosclerotic plaques (cerebral ischemic events within the last three months) confirmed by HR-MRI from July 2017 to August 2022 were retrospectively included in this study. The enrolled patients started statin therapy at baseline. All the patients underwent the follow-up HR-MRI examination after statin therapy for at least 3 months. A paired sample t-test and Wilcoxon rank sum test were used to evaluate the changes in plaque characteristics after statin therapy. Multivariate linear regression was further used to investigate the clinical factors associated with statin efficacy.

Results: A total of 48 patients (37 males; overall mean age = 60.2 ± 11.7 years) were included in this study. The follow-up time was 7.0 (5.6-12.0) months. In patients treated with statins for > 6 months (n = 31), plaque length, wall thickness, plaque burden, luminal stenosis and plaque enhancement were significantly reduced. Similar results were found in patients with good lipid control (n = 21). Younger age, lower BMI and hypertension were associated with decreased plaque burden. Lower BMI, hypertension and longer duration of statin therapy were associated with decreased plaque enhancement. Younger age and hypertension were associated with decreased luminal stenosis (all p < 0.05).

Conclusion: HR-MRI can effectively evaluate plaques changes after statin therapy. Statins can reduce plaque burden and stabilize plaques. The effect of statin may have a relationship with age, BMI, hypertension, and duration of statin therapy.

Clinical relevance statement: High-resolution MRI can be applied to evaluate the efficacy of statins on symptomatic intracranial atherosclerotic plaques. Long-term statin use and well-controlled blood lipid levels can help reduce plaque burden and stabilize plaques.

Key points: High-resolution MRI provides great help evaluating the changes of plaque characteristics after statin therapy. Efficacy of statins is associated with duration of use, controlled lipid levels, and clinical factors. High-resolution MRI can serve as an effective method for following-up symptomatic intracranial atherosclerosis.

Abstract Image

应用高分辨率磁共振成像评估他汀类药物对无症状颅内动脉粥样硬化的疗效。
目的利用高分辨率3.0 T磁共振血管壁成像(HR-MRI)研究他汀类药物对无症状颅内动脉粥样硬化斑块的疗效:回顾性纳入2017年7月至2022年8月期间经HR-MRI证实的无症状颅内动脉粥样硬化斑块(最近三个月内发生脑缺血事件)患者。入选患者在基线时开始接受他汀治疗。所有患者在他汀治疗至少3个月后接受了HR-MRI随访检查。采用配对样本t检验和Wilcoxon秩和检验来评估他汀治疗后斑块特征的变化。多变量线性回归进一步用于研究与他汀类药物疗效相关的临床因素:本研究共纳入 48 名患者(37 名男性;总平均年龄 = 60.2 ± 11.7 岁)。随访时间为 7.0 (5.6-12.0) 个月。在接受他汀类药物治疗超过 6 个月的患者中(31 人),斑块长度、壁厚、斑块负荷、管腔狭窄和斑块强化均显著减少。血脂控制良好的患者(21 人)也有类似的结果。年龄较小、体重指数较低和高血压与斑块负荷减少有关。较低的体重指数、高血压和较长的他汀类药物治疗时间与斑块强化减少有关。年龄越小、高血压与管腔狭窄程度越小有关(均为 p 结论:HR-MRI 能有效评估斑块:HR-MRI 可以有效评估他汀类药物治疗后斑块的变化。他汀类药物可减少斑块负荷并稳定斑块。他汀类药物的效果可能与年龄、体重指数、高血压和他汀类药物治疗的持续时间有关:高分辨率磁共振成像可用于评估他汀类药物对无症状颅内动脉粥样硬化斑块的疗效。长期服用他汀类药物和控制好血脂水平有助于减轻斑块负担和稳定斑块:高分辨率磁共振成像有助于评估他汀类药物治疗后斑块特征的变化。他汀类药物的疗效与使用时间、控制血脂水平和临床因素有关。高分辨率磁共振成像可作为随访无症状颅内动脉粥样硬化的有效方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Radiology
European Radiology 医学-核医学
CiteScore
11.60
自引率
8.50%
发文量
874
审稿时长
2-4 weeks
期刊介绍: European Radiology (ER) continuously updates scientific knowledge in radiology by publication of strong original articles and state-of-the-art reviews written by leading radiologists. A well balanced combination of review articles, original papers, short communications from European radiological congresses and information on society matters makes ER an indispensable source for current information in this field. This is the Journal of the European Society of Radiology, and the official journal of a number of societies. From 2004-2008 supplements to European Radiology were published under its companion, European Radiology Supplements, ISSN 1613-3749.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信